Google Rules U.S. Search Market, But Tech Giant Has Weaknesses
Google continues to smack home runs in search while hitting pop flies in other areas — at least so far.
(tags: google stocks)
Losing the American dream
The Dow is soaring, and the economy is growing. So why are so many Americans bearish?
(tags: economics stocks)
Pair Trade Updates - Homebuilders […]
Original post by FeedZilla
Home sales and a report on economic growth may help investors decide if they want to keep riding a bull market in stocks, while a torrent of quarterly earnings reports will no doubt cause some anxious moments.
Original post by FeedZilla
It’s an ill wind, indeed, that blows no company some good — or at least a bit of top-line growth. And that’s surely the case with Lindsay, a…
Original post by FeedZilla
Despite a late rally attempt, the NASDAQ couldn’t overcome earnings worries and finished Friday with a 1.2% loss.
Original post by FeedZilla
NYSE stocks fell hard Friday in heavy trade, after some high-profile earnings letdowns from Google ( GOOG) and Caterpillar (CAT).
Original post by FeedZilla
A trio of high-profile earnings shortfalls pushed stocks lower Friday, handing the market its second distribution day in the past three sessions.
Original post by FeedZilla
The mortgage lender bounced back after closing down 70% for the year Thursday on a rumor that a large lender pulled its credit line.
Original post by FeedZilla
SAN FRANCISCO (MarketWatch) — Roche Holdings Ltd. and Trimeris Inc. late Friday said that new interim results from an ongoing study demonstrate a high response rate with Fuzeon plus darunavir, regardless of existing protease inhibitor resistance. The data showed that about 64% of three-class, treatment-experienced patients achieved undetectable HIV at 24 weeks, and that baseline sensitivity to darunavir didn’t appear to influence patient response to the regimen, the companies said. Fuzeon, co-developed by Roche and Trimeris, is a fusion inhibitor available for the treatment of HIV, while darunavir is a commercially available, ritonavir-boosted protease inhibitor, marketed by Tibotec Therapeutics. The study was presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Sydney, Australia.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Original post by FeedZilla
SAN FRANCISCO (MarketWatch) — American Physicians Capital Inc. late Friday reported second-quarter net earnings of $16.3 million, or $1.44 a share, up 52% from $10.7 million, or 86 cents a share, in the year-ago period. The East Lansing, Mich.-based provider of medical professional liability insurance said net written premiums in the three months ended June 30 fell to $27 million from $30.1 million in the comparable period last year. Analysts polled by Thomson Financial were expecting, on average, a per-share profit of 91 cents. The company posted a combined ration of 58.7% in the second quarter versus 89.6% in the same period in 2006.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Original post by FeedZilla
SAN FRANCISCO (MarketWatch) — Wyeth said late Friday that a U.S. District Court has ruled in favor of the company in the St. Louis diet drug case, Lisa Dean v. Wyeth. Madison, N.J.-based Wyeth is a pharmaceutical and health-care products company.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Original post by FeedZilla